Trial
NCT05429762
Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Sanofi
Collaborators
—
Condition
Neoplasm
Intervention
Tusamitamab ravtansine
Why stopped
Tusamitamab ravtansine clinical development program is discontinued as CARMEN-LC03 trial did not meet dual primary endpoint of improving progression-free survival. The decision is not related to any safety concern.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-04-06